We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
NeuroMetrix Inc | NASDAQ:NURO | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.08 | 1.79% | 4.55 | 4.25 | 5.50 | 4.45 | 4.28 | 4.45 | 21,219 | 05:00:07 |
x
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
¨
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Delaware
|
04-3308180
|
(State or other jurisdiction of
|
(I.R.S. Employer Identification No.)
|
incorporation or organization)
|
|
|
|
1000 Winter Street, Waltham, Massachusetts
|
02451
|
(Address of principal executive offices)
|
(Zip Code)
|
Large accelerated filer
¨
|
Accelerated filer
¨
|
Non-accelerated filer
¨
|
Smaller reporting company
x
|
|
|
|
Emerging growth company
¨
|
|
||
|
|
|
Item 1.
|
|
|
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
Item 2.
|
||
|
|
|
Item 3.
|
||
|
|
|
Item 4.
|
||
|
|
|
|
||
|
|
|
Item 1.
|
||
|
|
|
Item 1A.
|
||
|
|
|
Item 2.
|
||
|
|
|
Item 3.
|
||
|
|
|
Item 4.
|
||
|
|
|
Item 5.
|
||
|
|
|
Item 6.
|
||
|
|
|
|
March 31, 2019
|
|
December 31, 2018 (a)
|
||||
|
(Unaudited)
|
|
|
||||
Assets
|
|
|
|
|
|
||
Current assets:
|
|
|
|
|
|
||
Cash and cash equivalents
|
$
|
7,200,795
|
|
|
$
|
6,780,429
|
|
Accounts receivable, net
|
972,352
|
|
|
1,082,957
|
|
||
Inventories
|
2,494,268
|
|
|
2,861,864
|
|
||
Prepaid expenses and other current assets
|
962,727
|
|
|
860,915
|
|
||
Total current assets
|
11,630,142
|
|
|
11,586,165
|
|
||
|
|
|
|
||||
Fixed assets, net
|
375,561
|
|
|
407,339
|
|
||
Right to use asset
|
1,870,979
|
|
|
1,968,062
|
|
||
Other long-term assets
|
30,081
|
|
|
30,314
|
|
||
Total assets
|
$
|
13,906,763
|
|
|
$
|
13,991,880
|
|
|
|
|
|
||||
Liabilities and Stockholders’ Equity
|
|
|
|
|
|
||
Current liabilities:
|
|
|
|
|
|
||
|
|
|
|
||||
Accounts payable
|
$
|
557,861
|
|
|
$
|
1,298,084
|
|
Accrued expenses and compensation
|
3,036,301
|
|
|
2,236,633
|
|
||
Accrued product returns
|
726,892
|
|
|
1,101,658
|
|
||
Deferred collaboration income
|
181,818
|
|
|
1,956,522
|
|
||
Total current liabilities
|
4,502,872
|
|
|
6,592,897
|
|
||
|
|
|
|
||||
Lease obligation, net of current portion
|
1,211,480
|
|
|
1,301,172
|
|
||
Total liabilities
|
5,714,352
|
|
|
7,894,069
|
|
||
|
|
|
|
||||
Commitments and contingencies
|
|
|
|
|
|
||
|
|
|
|
||||
Stockholders’ equity:
|
|
|
|
|
|
||
Preferred stock
|
—
|
|
|
—
|
|
||
Convertible preferred stock
|
15
|
|
|
18
|
|
||
Common stock, $0.0001 par value; 100,000,000 shares authorized at March 31, 2019 and December 31, 2018; 8,310,463 and 7,380,463 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively
|
831
|
|
|
738
|
|
||
Additional paid-in capital
|
197,157,649
|
|
|
197,113,646
|
|
||
Accumulated deficit
|
(188,966,084
|
)
|
|
(191,016,591
|
)
|
||
Total stockholders’ equity
|
8,192,411
|
|
|
6,097,811
|
|
||
Total liabilities and stockholders’ equity
|
$
|
13,906,763
|
|
|
$
|
13,991,880
|
|
|
Quarters Ended March 31,
|
||||||
|
2019
|
|
2018
|
||||
|
|
|
|
||||
Revenues
|
$
|
3,122,935
|
|
|
$
|
4,942,990
|
|
|
|
|
|
||||
Cost of revenues
|
2,324,231
|
|
|
2,955,260
|
|
||
|
|
|
|
||||
Gross profit
|
798,704
|
|
|
1,987,730
|
|
||
|
|
|
|
||||
Operating expenses:
|
|
|
|
|
|
||
Research and development
|
855,081
|
|
|
1,279,564
|
|
||
Sales and marketing
|
2,025,288
|
|
|
2,504,741
|
|
||
General and administrative
|
1,619,490
|
|
|
1,804,143
|
|
||
|
|
|
|
||||
Total operating expenses
|
4,499,859
|
|
|
5,588,448
|
|
||
|
|
|
|
||||
Loss from operations
|
(3,701,155
|
)
|
|
(3,600,718
|
)
|
||
|
|
|
|
||||
Other income:
|
|
|
|
||||
Collaboration income
|
5,734,849
|
|
|
4,755,705
|
|
||
Other income
|
16,813
|
|
|
11,265
|
|
||
|
|
|
|
||||
Total other income
|
5,751,662
|
|
|
4,766,970
|
|
||
|
|
|
|
||||
Net income
|
$
|
2,050,507
|
|
|
$
|
1,166,252
|
|
|
|
|
|
||||
Net income per common share applicable to common stockholders,
|
|
|
|
||||
Basic
|
$
|
0.26
|
|
|
$
|
0.18
|
|
Diluted
|
$
|
0.15
|
|
|
$
|
0.08
|
|
|
Series B – F
Convertible Preferred Stock |
|
Common
Stock |
|
Additional
Paid-In Capital |
|
Accumulated
Deficit |
|
Total
|
||||||||||||||||
|
Number of
Shares |
|
Amount
|
|
Number of
Shares |
|
Amount
|
|
|
|
|||||||||||||||
Balance at December 31, 2017
|
29,479.98
|
|
|
$
|
30
|
|
|
2,706,066
|
|
|
$
|
271
|
|
|
$
|
196,355,142
|
|
|
$
|
(191,338,054
|
)
|
|
$
|
5,017,389
|
|
Stock-based compensation expense
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
341,026
|
|
|
—
|
|
|
341,026
|
|
|||||
Issuance of common stock upon conversion of preferred stock
|
(11,666.35
|
)
|
|
(12
|
)
|
|
4,435,874
|
|
|
443
|
|
|
(431
|
)
|
|
—
|
|
|
—
|
|
|||||
Effect of adoption of ASC606
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
297,858
|
|
|
297,858
|
|
|||||
Net income
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,166,252
|
|
|
1,166,252
|
|
|||||
Balance at March 31, 2018
|
17,813.63
|
|
|
$
|
18
|
|
|
7,141,940
|
|
|
$
|
714
|
|
|
$
|
196,695,736
|
|
|
$
|
(189,873,944
|
)
|
|
$
|
6,822,524
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Series B – F
Convertible Preferred Stock |
|
Common
Stock |
|
Additional
Paid-In Capital |
|
Accumulated
Deficit |
|
Total
|
||||||||||||||||
|
Number of
Shares |
|
Amount
|
|
Number of
Shares |
|
Amount
|
|
|
|
|||||||||||||||
Balance at December 31, 2018
|
17,813.63
|
|
|
$
|
18
|
|
|
7,380,463
|
|
|
$
|
738
|
|
|
$
|
197,113,646
|
|
|
$
|
(191,016,591
|
)
|
|
$
|
6,097,811
|
|
Stock-based compensation expense
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
44,093
|
|
|
—
|
|
|
44,093
|
|
|||||
Issuance of common stock upon conversion of preferred stock
|
(2,445.90
|
)
|
|
(3
|
)
|
|
930,000
|
|
|
93
|
|
|
(90
|
)
|
|
—
|
|
|
—
|
|
|||||
Net income
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
2,050,507
|
|
|
2,050,507
|
|
|||||
Balance at March 31, 2019
|
15,367.73
|
|
|
$
|
15
|
|
|
8,310,463
|
|
|
$
|
831
|
|
|
$
|
197,157,649
|
|
|
$
|
(188,966,084
|
)
|
|
$
|
8,192,411
|
|
|
Three Months Ended March 31,
|
||||||
|
2019
|
|
2018
|
||||
Cash flows from operating activities:
|
|
|
|
|
|
||
Net income
|
$
|
2,050,507
|
|
|
$
|
1,166,252
|
|
Adjustments to reconcile net income to net cash provided by operating activities:
|
|
|
|
|
|
||
Depreciation
|
31,778
|
|
|
55,444
|
|
||
Stock-based compensation
|
44,093
|
|
|
341,026
|
|
||
Inventory provision
|
700,000
|
|
|
—
|
|
||
Changes in operating assets and liabilities:
|
|
|
|
|
|
||
Accounts receivable
|
110,605
|
|
|
814,108
|
|
||
Inventories
|
(182,404
|
)
|
|
283,909
|
|
||
Prepaid expenses and other current and long-term assets
|
(101,579
|
)
|
|
343,177
|
|
||
Accounts payable
|
(740,223
|
)
|
|
(369,665
|
)
|
||
Accrued expenses and compensation
|
657,059
|
|
|
(868
|
)
|
||
Accrued product returns
|
(374,766
|
)
|
|
(553,439
|
)
|
||
Deferred collaboration income
|
(1,774,704
|
)
|
|
—
|
|
||
Net cash provided by operating activities
|
420,366
|
|
|
2,079,944
|
|
||
|
|
|
|
||||
Cash flows from investing activities:
|
|
|
|
|
|
||
Purchases of fixed assets
|
—
|
|
|
(25,833
|
)
|
||
Net cash used in investing activities
|
—
|
|
|
(25,833
|
)
|
||
|
|
|
|
||||
Net increase in cash and cash equivalents
|
420,366
|
|
|
2,054,111
|
|
||
Cash and cash equivalents, beginning of period
|
6,780,429
|
|
|
4,043,681
|
|
||
Cash and cash equivalents, end of period
|
$
|
7,200,795
|
|
|
$
|
6,097,792
|
|
1.
|
Business and Basis of Presentation
|
|
As reported
|
|
Adjustments
|
|
Amounts under prior GAAP
|
||||||
|
|
|
|
|
|
||||||
Prepaid expenses and other current assets
|
$
|
962,727
|
|
|
$
|
44,852
|
|
|
$
|
1,007,579
|
|
Total current assets
|
$
|
11,630,142
|
|
|
$
|
44,852
|
|
|
$
|
11,674,994
|
|
Right of use asset
|
$
|
1,870,979
|
|
|
$
|
(1,870,979
|
)
|
|
$
|
—
|
|
Other long-term assets
|
$
|
30,081
|
|
|
$
|
34,363
|
|
|
$
|
64,444
|
|
Total assets
|
$
|
13,906,763
|
|
|
$
|
(1,791,764
|
)
|
|
$
|
12,114,999
|
|
Accrued expenses
|
$
|
3,036,301
|
|
|
$
|
(580,284
|
)
|
|
$
|
2,456,017
|
|
Total current liabilities
|
$
|
4,502,872
|
|
|
$
|
(580,284
|
)
|
|
$
|
3,922,588
|
|
Lease obligation - net of current portion
|
$
|
1,211,480
|
|
|
$
|
(1,211,480
|
)
|
|
$
|
—
|
|
Total liabilities
|
$
|
5,714,352
|
|
|
$
|
(1,791,764
|
)
|
|
$
|
3,922,588
|
|
|
As reported
|
|
Adjustments
|
|
Amounts under prior GAAP
|
||||||
|
|
|
|
|
|
||||||
Prepaid expenses and other current assets
|
$
|
860,915
|
|
|
$
|
44,852
|
|
|
$
|
905,767
|
|
Total current assets
|
$
|
11,586,165
|
|
|
$
|
44,852
|
|
|
$
|
11,631,017
|
|
Right of use asset
|
$
|
1,968,062
|
|
|
$
|
(1,968,062
|
)
|
|
$
|
—
|
|
Other long-term assets
|
$
|
30,314
|
|
|
$
|
44,578
|
|
|
$
|
74,892
|
|
Total assets
|
$
|
13,991,880
|
|
|
$
|
(1,878,632
|
)
|
|
$
|
12,113,248
|
|
Accrued expenses
|
$
|
2,236,633
|
|
|
$
|
(577,460
|
)
|
|
$
|
1,659,173
|
|
Total current liabilities
|
$
|
6,592,897
|
|
|
$
|
(577,460
|
)
|
|
$
|
6,015,437
|
|
Lease obligation - net of current portion
|
$
|
1,301,172
|
|
|
$
|
(1,301,172
|
)
|
|
$
|
—
|
|
Total liabilities
|
$
|
7,894,069
|
|
|
$
|
(1,878,632
|
)
|
|
$
|
6,015,437
|
|
2.
|
Comprehensive Income
|
3.
|
Net Income Per Common Share
|
|
Quarters Ended March 31,
|
||||||
|
2019
|
|
2018
|
||||
Net income applicable to common stockholders
|
$
|
2,050,507
|
|
|
$
|
1,166,252
|
|
|
|
|
|
||||
Weighted average number of common shares outstanding, basic
|
7,741,463
|
|
|
6,345,719
|
|
||
Dilutive convertible preferred stock
|
6,222,746
|
|
|
7,380,895
|
|
||
Weighted average number of common shares outstanding, dilutive
|
13,964,209
|
|
|
13,726,614
|
|
||
|
|
|
|
||||
Net income per common share applicable to common stockholders, basic
|
$
|
0.26
|
|
|
$
|
0.18
|
|
Net income per common share applicable to common stockholders, diluted
|
$
|
0.15
|
|
|
$
|
0.08
|
|
4.
|
Inventories
|
|
March 31, 2019
|
|
December 31, 2018
|
||||
Purchased components
|
$
|
1,710,368
|
|
|
$
|
1,767,674
|
|
Finished goods
|
783,900
|
|
|
1,094,190
|
|
||
|
$
|
2,494,268
|
|
|
$
|
2,861,864
|
|
5.
|
Accrued Expenses and Compensation
|
|
March 31, 2019
|
|
December 31, 2018
|
||||
Professional services
|
$
|
863,000
|
|
|
$
|
391,000
|
|
Lease obligation, current portion
|
580,284
|
|
|
577,460
|
|
||
Compensation
|
467,522
|
|
|
213,756
|
|
||
Technology fees
|
450,000
|
|
|
450,000
|
|
||
Contract manufacturer
|
320,000
|
|
|
160,000
|
|
||
Warranty reserve
|
116,000
|
|
|
129,837
|
|
||
Advertising and promotion
|
61,200
|
|
|
171,000
|
|
||
Other
|
178,295
|
|
|
143,580
|
|
||
|
$
|
3,036,301
|
|
|
$
|
2,236,633
|
|
6.
|
Leases
|
2019
|
|
$
|
473,413
|
|
2020
|
|
641,193
|
|
|
2021
|
|
653,164
|
|
|
2022
|
|
247,347
|
|
|
2023
|
|
165,785
|
|
|
2024
|
|
165,785
|
|
|
2025
|
|
117,431
|
|
|
Total minimum lease payments
|
|
$
|
2,464,118
|
|
|
|
|
||
Weighted-average discount rate, 14.6%
|
|
$
|
672,354
|
|
Lease obligation, current portion
|
|
580,284
|
|
|
Lease obligation, net of current portion
|
|
1,211,480
|
|
|
|
|
$
|
2,464,118
|
|
7.
|
Fair Value Measurements
|
|
|
|
Fair Value Measurements at March 31, 2019 Using
|
||||||||||||
|
March 31, 2019
|
|
Quoted Prices in
Active Markets for Identical Assets (Level 1) |
|
Significant Other
Observable Inputs (Level 2) |
|
Significant
Unobservable Inputs (Level 3) |
||||||||
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cash equivalents
|
$
|
4,966,621
|
|
|
$
|
4,966,621
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Total
|
$
|
4,966,621
|
|
|
$
|
4,966,621
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
|
|
Fair Value Measurements at December 31, 2018 Using
|
||||||||||||
|
December 31, 2018
|
|
Quoted Prices in
Active Markets for Identical Assets (Level 1) |
|
Significant Other
Observable Inputs (Level 2) |
|
Significant
Unobservable Inputs (Level 3) |
||||||||
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cash equivalents
|
$
|
4,284,928
|
|
|
$
|
4,284,928
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Total
|
$
|
4,284,928
|
|
|
$
|
4,284,928
|
|
|
$
|
—
|
|
|
$
|
—
|
|
8.
|
Credit Facility
|
9.
|
Stockholders’ Equity
|
|
March 31, 2019
|
|
December 31, 2018
|
||||
Preferred stock, $0.001 par value; 5,000,000 shares authorized at March 31, 2019 and December 31, 2018; no shares issued and outstanding at March 31, 2019 and December 31, 2018
|
$
|
—
|
|
|
$
|
—
|
|
Series B convertible preferred stock, $0.001 par value; 147,000 shares designated at March 31, 2019 and December 31, 2018; 200 shares issued and outstanding at March 31, 2019 and December 31, 2018
|
$
|
1
|
|
|
$
|
1
|
|
Series D convertible preferred stock, $0.001 par value; 21,300 shares designated at March 31, 2019 and December 31, 2018; 13,526.93 and 14,052.93 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively
|
$
|
13
|
|
|
$
|
14
|
|
Series E convertible preferred stock, $0.001 par value; 7,000 shares designated at March 31, 2019 and December 31, 2018; 1,340.80 and 3,260.70 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively
|
$
|
1
|
|
|
$
|
3
|
|
|
Quarters Ended March 31,
|
|
|
|||||||||||
|
2019
|
|
2018
|
|
Change
|
|
% Change
|
|||||||
|
(in thousands)
|
|
|
|||||||||||
Revenues
|
$
|
3,122.9
|
|
|
$
|
4,943.0
|
|
|
$
|
(1,820.1
|
)
|
|
(36.8
|
)%
|
|
Quarters Ended March 31,
|
|
|
|||||||||||
|
2019
|
|
2018
|
|
Change
|
|
% Change
|
|||||||
|
(in thousands)
|
|
|
|||||||||||
Cost of revenues
|
$
|
2,324.2
|
|
|
$
|
2,955.3
|
|
|
$
|
(631.1
|
)
|
|
(21.4
|
)%
|
|
|
|
|
|
|
|
|
|||||||
Gross profit
|
$
|
798.7
|
|
|
$
|
1,987.7
|
|
|
$
|
(1,189.0
|
)
|
|
(59.8
|
)%
|
|
Quarters Ended March 31,
|
|
|
|||||||||||
|
2019
|
|
2018
|
|
Change
|
|
% Change
|
|||||||
|
(in thousands)
|
|
|
|||||||||||
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|||
Research and development
|
$
|
855.1
|
|
|
$
|
1,279.6
|
|
|
$
|
(424.5
|
)
|
|
(33.2
|
)%
|
Sales and marketing
|
2,025.3
|
|
|
2,504.7
|
|
|
(479.4
|
)
|
|
(19.1
|
)%
|
|||
General and administrative
|
1,619.5
|
|
|
1,804.1
|
|
|
(184.6
|
)
|
|
(10.2
|
)%
|
|||
Total operating expenses
|
$
|
4,499.9
|
|
|
$
|
5,588.4
|
|
|
$
|
(1,088.5
|
)
|
|
(19.5
|
)%
|
|
Quarters Ended March 31,
|
|
|
|||||||||||
|
2019
|
|
2018
|
|
Change
|
|
% Change
|
|||||||
|
(in thousands)
|
|
|
|||||||||||
|
|
|
|
|
|
|
|
|||||||
Collaboration income
|
$
|
5,734.8
|
|
|
$
|
4,755.7
|
|
|
$
|
979.1
|
|
|
20.6
|
%
|
|
Quarters Ended March 31,
|
|
|
|||||||||||
|
2019
|
|
2018
|
|
Change
|
|
% Change
|
|||||||
|
(in thousands)
|
|
|
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||
Other income
|
$
|
16.8
|
|
|
$
|
11.3
|
|
|
$
|
5.5
|
|
|
48.7
|
%
|
|
March 31, 2019
|
|
December 31, 2018
|
|
Change
|
|
% Change
|
|||||||
|
($ in thousands)
|
|
|
|||||||||||
|
|
|
|
|
|
|
|
|||||||
Cash and cash equivalents
|
$
|
7,200.8
|
|
|
$
|
6,780.4
|
|
|
$
|
420.4
|
|
|
6.2
|
%
|
|
Quarters Ended March 31,
|
|
Year Ended
December 31, |
||
|
2019
|
|
2018
|
|
2018
|
|
|
|
|
|
|
Days sales outstanding (days)
|
30
|
|
36
|
|
39
|
Inventory turnover rate (times per year)
|
3.5
|
|
5.9
|
|
3.5
|
|
Three Months Ended March 31,
|
||||||
|
2019
|
|
2018
|
||||
|
(in thousands)
|
||||||
Net cash used in operating activities (excluding collaboration income)
|
$
|
(3,539.7
|
)
|
|
$
|
(2,675.8
|
)
|
Net cash provided by collaboration income
|
3,960.1
|
|
|
4,755.7
|
|
||
Net cash provided by operating activities
|
$
|
420.4
|
|
|
$
|
2,079.9
|
|
•
|
inability to efficiently create market demand for Quell at profitable pricing levels through our TV and digital marketing efforts, or any other marketing efforts we may adopt;
|
•
|
changes we may make to our pricing and marketing strategy with respect to Quell or our other products;
|
•
|
manufacturing issues with Quell or our other products;
|
•
|
inability to increase adoption of DPNCheck within the Medicare Advantage market and Outside the United States (OUS) markets;
|
•
|
regulatory inquiries or issues affecting our products;
|
•
|
unfavorable changes to current Medicare, Medicare Advantage and commercial payer payment policies;
|
•
|
changes to payor policies under the Patient Protection and Affordable Care Act;
|
•
|
the outcome of the ongoing FTC investigation regarding Quell;
|
•
|
unfavorable experiences by patients and physicians using Quell and our other products; and,
|
•
|
physicians’ or patients' reluctance to alter their existing practices and adopt the use of our devices.
|
|
|
NEUROMETRIX, INC.
|
|
|
|
April 25, 2019
|
/s/
|
SHAI N. GOZANI, M.D., PH. D.
|
|
|
Shai N. Gozani, M.D., Ph. D.
|
|
|
Chairman, President and Chief Executive Officer
|
|
|
|
April 25, 2019
|
/s/
|
THOMAS T. HIGGINS
|
|
|
Thomas T. Higgins
|
|
|
Senior Vice President, Chief Financial Officer and Treasurer
|
Exhibit No.
|
|
Description
|
|
|
|
|
Certification of Principal Executive Officer Under Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended, and pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002. Filed herewith.
|
|
|
|
|
|
Certification of Principal Financial Officer Required Under Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended, and pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Filed herewith.
|
|
|
|
|
|
Certification of Principal Executive Officer and Principal Financial Officer Required Under Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350. Furnished herewith.
|
|
|
|
|
|
Eleventh Modification to Loan and Security Agreement with Comerica Bank, dated March 25, 2019. Filed herewith.
|
|
|
|
|
101
|
|
The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, formatted in XBRL (eXtensible Business Reporting Language): (i) Balance Sheets at March 31, 2019 and December 31, 2018, (ii) Statements of Operations for the three months ended March 31, 2019 and 2018, (iii) Statements of Changes in Stockholders' Equity for the three months ended March 31, 2019 and 2018, (iv) Statements of Cash Flows for the three months ended March 31, 2019 and 2018, and (v) Notes to Financial Statements.
|
|
|
1 Year NeuroMetrix Chart |
1 Month NeuroMetrix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions